GU Cancers 2024 | Evaluating the role of salvage radiotherapy in prostate cancer

Alan Dal Pra, MD, University of Miami, Miami, FL, comments on the utility of salvage radiotherapy in prostate cancer following results of the Phase III EMBARK trial (NCT02319837). The stratification of patients needs to be improved to identify patients who will benefit from salvage radiotherapy or systemic therapy. Genomic testing and elucidating novel prognostic and predicative biomarkers will be essential to stratify patients. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.